Correspondence 0000950170-24-012319 from Evoke Pharma Inc (EVOK) (CIK 0001403708)
Evoke Pharma Inc (EVOK) (CIK 0001403708)
Date: Feb. 7, 2024 · CIK: 0001403708 · Accession: 0000950170-24-012319
AI Filing Summary & Sentiment
File numbers found in text: 333-275443
Letter
Re: Evoke Pharma, Inc.
Evoke Pharma, Inc.
420 Stevens Avenue, Suite 230
Solana Beach, CA 92075
February 7, 2024
VIA EDGAR
Office of Life Sciences Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street N.E. Washington, D.C. 20549
Registration Statement on Form S-1, as amended
File No. 333-275443
Ladies and Gentlemen:
Pursuant to Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, the undersigned, on behalf of Evoke Pharma, Inc. (the “Company”), respectfully requests that the effective date of the Registration Statement on Form S-1 referred to above be accelerated so that it will become effective at 5:00 P.M. Eastern Time on February 8, 2024, or as soon as practicable thereafter.
Please contact Anthony Gostanian of Latham & Watkins LLP, counsel to the Company, at (858) 523-3969, to provide notice of effectiveness, or if you have any questions or require additional information regarding this matter. Thank you for your assistance and cooperation in this matter.
Very truly yours,
EVOKE PHARMA, INC.
Show Raw Text
CORRESP 1 filename1.htm CORRESP Evoke Pharma, Inc. 420 Stevens Avenue, Suite 230 Solana Beach, CA 92075 February 7, 2024 VIA EDGAR Office of Life Sciences Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street N.E. Washington, D.C. 20549 Re: Evoke Pharma, Inc. Registration Statement on Form S-1, as amended File No. 333-275443 Ladies and Gentlemen: Pursuant to Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, the undersigned, on behalf of Evoke Pharma, Inc. (the “Company”), respectfully requests that the effective date of the Registration Statement on Form S-1 referred to above be accelerated so that it will become effective at 5:00 P.M. Eastern Time on February 8, 2024, or as soon as practicable thereafter. Please contact Anthony Gostanian of Latham & Watkins LLP, counsel to the Company, at (858) 523-3969, to provide notice of effectiveness, or if you have any questions or require additional information regarding this matter. Thank you for your assistance and cooperation in this matter. Very truly yours, EVOKE PHARMA, INC. By: /s/ David A. Gonyer David A. Gonyer Chief Executive Officer cc: Matthew J. D’Onofrio, Evoke Pharma, Inc. Matthew T. Bush, Latham & Watkins LLP ||| Anthony Gostanian, Latham & Watkins LLP Richard A. Friedman, Sheppard, Mullin, Richter & Hampton LLP |||